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KL-6 is a glycoprotein found predominantly on type II pneumocytes and alveolar macrophages,  and 
often shows increased serum levels in patients with interstitial pneumonia.  We report a case of myco-
bacterium avium complex (MAC) infection whose disease activity was correlated with KL-6 levels in 
serum.  During treatment of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) with 
prednisolone,  chest image ﬁndings improved in association with decreased KL-6 levels.  Following 
tapering of prednisolone,  chest image ﬁndings deteriorated again as levels of KL-6 increased,  suggest-
ing recurrence of RA-ILD.  Bronchoscopic examination revealed active MAC infection.  Treatment of 
MAC infection not only improved chest image ﬁndings but also decreased KL-6 levels in serum,  sug-
gesting that KL-6 was increased by active MAC infection by itself,  not by recurrence of RA-ILD.  To 
the best of our knowledge,  this is the ﬁrst documentation of KL-6 elevation in serum in association 
with active MAC infection.
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P ulmonary involvement is a common extra-articu-lar feature of rheumatoid arthritis (RA).  While 
chest manifestations are varied,  interstitial lung dis-
ease (ILD) is the primary pulmonary characteristic of 
RA,  often associated with increased levels of KL-6 in 
serum.  Mycobacterium avium complex (MAC) is the 
most common cause of pulmonary disease worldwide 
among nontuberculous mycobacterium (NTM);  
however,  little is known about the association of NTM 
infection with serum levels of KL-6.
　 Here,  we report a case of pulmonary MAC infec-
tion associated with increased serum KL-6 levels while 
under treatment for RA-ILD.  Increased KL-6 levels 
suggested worsening of ILD.  However,  the patient 
was diagnosed with pulmonary MAC infection.  Treat-
ment for MAC infection not only improved chest image 
ﬁndings,  but also decreased KL-6 levels,  suggesting 
that pulmonary MAC infection by itself increased 
KL-6 serum levels.
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Case Report
　 A 30-year-old female with RA,  diagnosed based on 
ACR/EULAR criteria,  was admitted to our hospital 
due to aggravation of image ﬁndings.  The patient had 
no history of smoking.  She had been diagnosed with 
RA-ILD,  compatible with organized pneumonia (OP) 
pattern,  based on chest image ﬁndings,  clinical 
course,  increased serum KL-6 levels,  and increased 
number of lymphocytes in bronchial alveolar lavage 
(BAL) ﬂuid one and a half years ago.  Treatment of 
oral prednisolone 20mg/day was initiated.  The treat-
ment went well,  and the dose of prednisolone was 
gradually decreased.  RA was stable throughout the 
treatment course.
　 Six months after initiation of prednisolone treat-
ment at a dose of 4mg/day,  however,  chest image 
ﬁndings deteriorated and serum KL-6 levels increased.  
Sputum smear examination and culture test for myco-
bacteriosis were all negative.  Methotrexate,  which 
had been administered for rheumatic control,  was 
discontinued on suspicion of drug-induced lung injury.  
The dose of prednisolone was increased,  and tacroli-
mus was added for treatment of exacerbation of 
RA-ILD,  but chest image ﬁndings and KL-6 levels 
showed no improvement.
　 The patientʼs vital signs on arrival were as follows:  
body temperature,  36.7℃; blood pressure,  102/68 
mmHg; pulse rate,  93/min; respiratory rate＜20/min; 
and oxygen saturation,  96  (room air).  She reported 
feeling slightly tired,  but had few complaints about 
respiratory or joint symptoms.  On auscultation,  no 
crackles or wheezes were heard in either lung.  A 
chest X-ray showed bilateral shadows and chest com-
puted tomography (CT) scan further demonstrated 
inﬁltrates and granular patterns in bilateral middle to 
lower lobes (Fig.  1).  Neither restrictive nor obstruc-
tive impairment was seen on pulmonary function test.  
Blood examination revealed leukocytosis (white blood 
cell count: 10,870/µl) with a leftward shift,  probably 
due to prednisolone therapy.  Inﬂammation reaction 
(C-reactive protein; CRP) was not increased,  and liver 
and kidney functions were normal.  Serum levels of 
surfactant protein-D (SP-D) were normal,  and levels 
of sialylated carbohydrate antigen KL-6 (KL-6:  
1,153U/ml) in serum were increased.  Serum levels of 
MMP-3 were slightly increased.  Serum beta-D glu-
can,  galactomannan antigen,  and cryptococcal antigen 
were all negative.  Repeated sputum examination for 
several months demonstrated no evidence of infection,  
218 Acta Med.  Okayama　Vol.  70,  No.  3Waseda et al.
A B
Fig. 1　 Chest X-ray and CT images: A chest X-ray showed bilateral shadows in lower lung ﬁelds (A); inﬁltrates and granular patterns in 
bilateral middle to lower lobes were observed in chest high-resolution CT (B).
including NTM.
　 After admission,  BAL was performed.  The results 
revealed increased total cell number (3.5×105/ml) 
with a high ratio of lymphocyte (29 ),  and CD4/
CD8 ratio in BAL ﬂuid was increased (8.76).  Direct 
smear examination of BAL ﬂuid for mycobacterium 
infection demonstrated Gaﬀky 5 and culture examina-
tion proved nontuberculous mycobacterium infection 
(M. avium) (Table 1).  Multi-drug therapy including 
clarithromycin (CAM; 600mg/day),  rifampicin 
(RFP; 450mg/day) and ethambutol (EB; 500mg/day) 
was initiated.  Treatment was eﬀective,  and chest 
image ﬁndings improved,  associated with decreasing 
levels of KL-6 in serum (Fig.  2).
Discussion
　 To the best of our knowledge,  this is the ﬁrst 
reported case of MAC infection in association with 
increased KL-6 levels in serum.  Following treatment 
for MAC infection,  chest image appearance improved,  
and KL-6 levels decreased.  Therefore,  active MAC 
infection by itself appeared to increase serum KL-6 
levels,  and disease activity of MAC was correlated 
with KL-6 levels in our case.
　 KL-6 is a glycoprotein found predominantly on type 
II pneumocytes and alveolar macrophages.  Increased 
serum KL-6 levels in patients with interstitial pneu-
monia have been reported [1-3],  and serum KL-6 
elevation may be also caused by diseases such as 
hypersensitivity pneumonitis,  pulmonary alveolar pro-
teinosis,  lung cancer,  pneumocystis pneumonia and 
drug-induced pneumonia.  Although there is a study 
describing increased KL-6 levels in epithelial lining 
ﬂuid of patients with MAC infection [4],  little is 
known about serum KL-6 levels in NTM,  including 
MAC.  A few studies have shown that serum KL-6 
levels were signiﬁcantly higher in the patients with 
pulmonary tuberculosis than in healthy controls [5].  
The mechanism of how KL-6 secretion is increased in 
pulmonary tuberculosis remains uncertain.  When 
type-2 pneumocytes and bronchial epithelial cells are 
stimulated or injured by mycobacterium tuberculosis 
infection,  KL-6 might be more strongly expressed on 
the surface membrane.  Further investigation,  includ-
ing clinical studies,  will be necessary to clarify if 
KL-6 levels in serum of patients with pulmonary MAC 
infection are increased compared to healthy subjects,  
and if those levels are correlated with disease activ-
ity.
　 In the present case,  underlying RA-ILD made MAC 
infection diagnosis diﬃcult.  The chest image ﬁndings 
aﬀected with the RA-ILD OP pattern improved at ﬁrst 
following treatment with prednisolone,  with an associ-
ated decrease in KL-6 levels,  suggesting that KL-6 
levels were increased by RA-ILD alone.  However,  
chest findings subsequently deteriorated with 
increased levels of KL-6.  It has been reported that 
OP with elevated serum KL-6 is prone to disease 
recurrence and requires treatment with prednisolone 
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Table 1　 Raboratory ﬁndings on admission.
Peripheral Blood Pulmonary function test
WBC 10,870 /µl γ-GTP 16 IU/l VC 2.52 L
　Nt 92.3 % LDH 195 IU/l %VC 93.0 %
　Ly 5.8 % BUN 14.1 mg/dl FEV1.0 2.23 L
　Mo 1.7 % Cr 0.68 mg/dl FEV1.0% 84.8 %
　Eo 0.1 % Na 139 mEq/dl
　Ba 0.1 % K 4.8 mEq/dl BAL
RBC 514 ×104/µl Cl 108 mEq/dl Total cells 3.5 ×105/µl
Hb 13.3 g/dl CRP 0.07 mg/dl 　Macrophages 65.0 %
PLT 33.4 ×104/µl RF 8.6 IU/ml 　Ly 29.0 %
MMP-3 86.1 ng/ml 　Nt 6.0 %
Blood Chemistory KL-6 1,153 U/ml 　Eo 0 %
TP 6.8 g/dl SP-D 73.7 ng/ml Lymphocyte subset
Alb 4.5 g/dl β-D glucan ＜6.0 pg/ml 　CD4＋/CD8＋ 8.76
T.Bil 0.59 mg/dl Aspergillus (－) Smea exam (＋)
AST 23 IU/l Cryptococcus (－) Culture exam M.avium
ALT 9 IU/l QFT-3G (－)
[6].  Image ﬁndings and serum KL-6 elevation showed 
no improvement even with intensive treatment of 
RA-ILD,  but were ﬁnally ameliorated by the treat-
ment of NTM infection,  with an associated decrease 
in KL-6 levels.  Therefore,  it appears that KL-6 
levels were increased by MAC infection,  not by 
recurrence of RA-ILD.
　 One might wonder whether underlying RA-ILD 
could aﬀect the MAC-associated increase in KL-6 even 
though RA-ILD was well controlled by prednisolone 
therapy.  RA-ILD with MAC infection might enhance 
secretion of KL-6 from alveolar type 2 cells even 
though RA-ILD was well controlled,  and its secretion 
might be enhanced compared to MAC infection alone.  
To clarify this issue,  it is necessary to compare KL-6 
levels in NTM infection alone with NTM associated 
with stable RA-ILD.
　 ILD is the most common manifestation of rheuma-
toid lung disease [7-9],  and is a source of substantial 
morbidity and mortality for aﬀected patients.  The 
chest manifestations of RA-ILD are varied and include 
pleuritis,  pleural eﬀusions,  and airway diseases such 
as bronchiolitis obliterans,  rheumatoid nodules and 
ILD [10].  In the present case,  the chest image ﬁnd-
ings of MAC infection resembled RA-ILD,  which made 
it diﬃcult for us to diagnose MAC.  Granular shadows 
had been also observed with consolidation at the time 
of the RA-ILD diagnosis,  and both had improved by 
prednisolone therapy.  Later,  when granular shadows 
appeared and deteriorated,  pulmonary MAC infection 
should have been a diﬀerential diagnosis; however,  it 
can be diﬃcult to distinguish RA-ILD from MAC 
infection simply with chest image ﬁndings.  It is also 
unclear when this patient was infected with MAC.  
RA-ILD in this case had been well treated with pred-
nisolone,  with an associated decline of serum KL-6 
levels,  suggesting that pulmonary MAC infection was 
not very active when serum KL-6 stayed at low levels.
　 In summary,  we experienced a case of pulmonary 
MAC infection in which serum KL-6 levels were cor-
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Fig. 2　 Clinical course of treatment: The image ﬁndings deteriorated in association with serum KL-6 elevation,  and showed no improve-
ment with intensive treatment of RA-ILD such as prednisolone increase.  Bronchoscopic examination including BAL revealed pulmonary 
NTM infection,  and multi-drug therapy for pulmonary NTM was initiated.  Granular shadows regressed and serum KL-6 levels decreased to 
normal level in several months.
related with disease activity of MAC in RA-ILD.  The 
chest image ﬁndings of RA-ILD are complicated,  and 
may resemble associated NTM infection,  including 
MAC.  This case indicates that pulmonary MAC infec-
tion should be included in the diﬀerential diagnosis 
when elevated serum KL-6 levels are observed,  even 
in patients with RA-ILD.
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